Purchase this article with an account.
Stephen G Schwartz, Kamyar Vaziri, Krishna S Kishor, Jorge Fortun, Harry W Flynn; Rates of Retinal Detachment following Retisert and Ozurdex Implants. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1053.
Download citation file:
© 2017 Association for Research in Vision and Ophthalmology.
To evaluate the rates of retinal detachment (RD) following Retisert (Bausch + Lomb, Madison, NJ) and Ozurdex (Allergan, Irvine, CA) corticosteroid implants.
This is a retrospective and cross-sectional study utilizing medical records of patients included in the insurance claim-based MarketScan databases from the years 2007-2013 with a record of either Retisert or Ozurdex implants. Patients with continuous insurance and records of Retisert or Ozurdex implantation were identified. Unfortunately, not all patients in the database had the eye laterality (OD or OS) coded at each visit. Therefore, cases of “definite” (eye laterality coded each visit and the same each visit) and “presumed” (eye laterality not coded) RD following these implant procedures within 1 and 3 months and were queried. “Definite” RDs definitely occurred in the eye that received the implant. “Presumed” RDs (including all patients in this series) probably occurred in the eye that received the implant, but it is possible that this group includes some nonimplanted fellow eyes. Patients with records of other ophthalmic surgeries or procedures between their implant and RD were excluded.
Overall, records of 6,434 corticosteroid implants (320 Retisert implants and 6,114 Ozurdex implants) among 3,257 patients with at least 1 month of continuous health insurance were analyzed. At 1 month, the cumulative incidence of ‘presumed’ postimplantation RD was significantly lower for Ozurdex (0.1 ± 0.04%) than for Retisert (1.3 ± 0.6%, P = 0.001). Also at 1 month, the cumulative incidence of ‘definite’ postimplantation RD was significantly lower for Ozurdex (0.08 ± 0.05%) than for Retisert (0.5 ± 0.5%, P = 0.02). At 3 months, the cumulative incidence of ‘presumed’ postimplantation RD was significantly lower for Ozurdex (0.46 ± 0.09%) than for Retisert (2.1 ± 0.83%, P = 0.004). Also at 3 months, the cumulative incidence of ‘definite’ postimplantation RD was nonsignificantly lower for Ozurdex (0.34 ± 0.1%) than for Retisert (0.6 ± 0.59%, P = 0.46).
In this insurance-claim-based data set, the rates of postimplantation RD within 3 months were less than 0.5% for Ozurdex and about 1% for Retisert. These results may be useful for counseling individual patients about risks of these implants.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only